Ratings MedinCell LIQUIDNET SYSTEMS

Equities

FR0004065605

End-of-day quote LIQUIDNET SYSTEMS Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	-.--%

06-10	Transcript : MedinCell S.A., 2024 Earnings Call, Jun 10, 2024
06-10	Medincell: a 'new era' after a 'pivotal' 2023	CF

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
MEDINCELL	-.--%	475M	-
ELI LILLY AND COMPANY	+48.39%	765B	C+
JOHNSON & JOHNSON	-6.13%	354B	C+
MERCK & CO., INC.	+20.61%	331B	B-
ABBVIE INC.	+10.00%	299B	C+
ASTRAZENECA PLC	+18.87%	248B	B+
ROCHE HOLDING AG	-1.96%	219B	A+
NOVARTIS AG	+11.11%	216B	B-
AMGEN INC.	+5.80%	164B	C+
PFIZER, INC.	-2.50%	162B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes